|Application ||WB, E|
|Calculated MW||46598 Da|
|Antigen Region||46-72 aa|
|Other Names||DNA dC->dU-editing enzyme APOBEC-3D, A3D, 354-, APOBEC3D|
|Target/Specificity||This APOBEC3D antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 46-72 amino acids from the N-terminal region of human APOBEC3D.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||APOBEC3D Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. Exhibits antiviral activity against vif-deficient HIV-1. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination- independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single-or double- stranded RNA. May inhibit the mobility of LTR and non-LTR retrotransposons.|
|Cellular Location||Cytoplasm. Cytoplasm, P-body.|
|Tissue Location||Expressed in lymphoid organs. Also detected in non-lymphoid tissues including lung|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Unknown. Unable to reduce HIV-1 infectivity in vitro.
Zhang, W., et al. PLoS ONE 3 (12), E3963 (2008) :
Dang, Y., et al. J. Virol. 80(21):10522-10533(2006)
Stenglein, M.D., et al. J. Biol. Chem. 281(25):16837-16841(2006)
Conticello, S.G., et al. Mol. Biol. Evol. 22(2):367-377(2005)
Harris, R.S., et al. Nat. Rev. Immunol. 4(11):868-877(2004)
If you have any additional inquiries please email technical services at email@example.com.